Technical Analysis for ORMP - Oramed Pharmaceuticals Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical ORMP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 22 | 20 DMA Support | Bullish | 0.00% |
| Mar 22 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Mar 22 | Upper Bollinger Band Walk | Strength | 0.00% |
| Mar 22 | Down 3 Days in a Row | Weakness | 0.00% |
| Mar 21 | Fell Below 50 DMA | Bearish | -0.62% |
| Mar 21 | 20 DMA Support | Bullish | -0.62% |
| Mar 21 | Bollinger Band Squeeze | Range Contraction | -0.62% |
| Mar 21 | Upper Bollinger Band Walk | Strength | -0.62% |
| Mar 21 | BB Squeeze + Upper Band Touch | Range Contraction | -0.62% |
| Mar 21 | Upper Bollinger Band Touch | Strength | -0.62% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-28
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Oramed Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's products primarily comprise ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone that is in per-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Jerusalem, Israel.
Medicine Chemistry Pharmaceutical Pharmaceutical Industry Diabetes Medication Pharmaceutical Industry In China Endocrine System Dosage Forms Insulin Peptide Hormones Treatment Of Diabetes Glucagon Like Peptide 1 Tablet Pharmaceutical Solutions
Medicine Chemistry Pharmaceutical Pharmaceutical Industry Diabetes Medication Pharmaceutical Industry In China Endocrine System Dosage Forms Insulin Peptide Hormones Treatment Of Diabetes Glucagon Like Peptide 1 Tablet Pharmaceutical Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ORMP news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 8.59 |
| 52 Week Low | 2.78 |
| Average Volume | 37,469 |
| 200-Day Moving Average | 4.535 |
| 50-Day Moving Average | 3.2778 |
| 20-Day Moving Average | 3.2198 |
| 10-Day Moving Average | 3.2475 |
| Average True Range | 0.0899 |
| ADX | 14.57 |
| +DI | 19.3738 |
| -DI | 23.657 |
| Chandelier Exit (Long, 3 ATRs ) | 3.095 |
| Chandelier Exit (Short, 3 ATRs ) | 3.3697 |
| Upper Bollinger Band | 3.314 |
| Lower Bollinger Band | 3.1256 |
| Percent B (%b) | 0.5 |
| BandWidth | 5.851295 |
| MACD Line | -0.0051 |
| MACD Signal Line | -0.0148 |
| MACD Histogram | 0.0096 |
| Fundamentals | Value |
|---|---|
| Market Cap | 42.89 Million |
| Num Shares | 13.3 Million |
| EPS | -0.95 |
| Price-to-Earnings (P/E) Ratio | -3.39 |
| Price-to-Sales | 59.88 |
| Price-to-Book | 6.62 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.31 | ||||
| Resistance 3 (R3) | 3.31 | 3.28 | 3.30 | ||
| Resistance 2 (R2) | 3.28 | 3.26 | 3.28 | 3.29 | |
| Resistance 1 (R1) | 3.25 | 3.24 | 3.24 | 3.25 | 3.28 |
| Pivot Point | 3.22 | 3.22 | 3.21 | 3.22 | 3.22 |
| Support 1 (S1) | 3.19 | 3.20 | 3.18 | 3.19 | 3.16 |
| Support 2 (S2) | 3.16 | 3.18 | 3.16 | 3.15 | |
| Support 3 (S3) | 3.13 | 3.16 | 3.15 | ||
| Support 4 (S4) | 3.13 |
